FDA-endorsed inhibitors of CTLA-4 and PD-1 (nivolumab) have been created, and their blend with radiotherapy and chemotherapy has been displayed to further develop endurance in some GBM patients (38). This evidence concerns the gene CTLA4 and glioblastoma.